Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas,while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
10 μg | 約5 days | ¥ 107,000 |
50 μg | 約5 days | ¥ 321,500 |
500 μg | 約5 days | ¥ 1,698,500 |
1 mg | 約5 days | ¥ 2,545,500 |
説明 | Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas,while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |
Species | Human |
Expression Host | HEK293 Cells |
Tag | N-Twin strep-Flag |
Accession Number | P56856-2 |
別名 | Claudin 18.2, CLDN18, Claudin-18, CLDN18.2, Claudin-18.2 |
Amino Acid | Met1-Ala200 |
Construction | Met1-Ala200 |
Protein Purity | Greater than 70% as determined by reducing SDS-PAGE. Greater than 70% as determined by SEC-HPLC. |
分子量 | 18-22 kDa (reducing condition) |
Endotoxin | < 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
Formulation | Supplied as a 0.2 μm filtered solution of 50 mM HEPES, 150 mM NaCl, 0.06% DDM, 0.012% CHS, 10% Glycerol, pH 7.5. |
Stability & Storage |
Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted protein solutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping |
In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
Research Background | Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas,while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
Claudin-18.2 Protein, Human, Recombinant (Twin strep & Flag) Claudin 18.2 CLDN18 CLDN 18 Claudin-18 CLDN18.2 CLDN-18 Claudin-18.2 recombinant recombinant-proteins proteins protein